Apple has secured a major victory for its redesigned smartwatches as per the latest decision from the US International Trade Commission. The federal agency ruled against reinstating an import ban on Apple Watches, allowing the tech giant to continue selling its devices with a reworked blood-oxygen monitoring technology.
The ITC decided to terminate the case and refer to a preliminary ruling from one of its judges in March that claimed that Apple’s redesigned smartwatches don’t infringe on patents held by Masimo, the medical tech company that has long been embroiled in lawsuits surrounding the Apple Watch. Apple thanked the ITC in a statement, adding that “Masimo has waged a relentless legal campaign against Apple and nearly all of its claims have been rejected.” We reached out to Masimo for comment and will update the story when we hear back.
The latest decision could offer some closure to the longstanding legal feud between Masimo and Apple. The patent battle dates back to 2021 with Masimo’s first filing against Apple that requested an import ban on Apple Watches. The ITC ended up ruling that Apple violated Masimo’s patents, resulting in the previous import ban and the Apple Watch maker redesigning the blood-oxygen reading feature in certain models. However, Masimo wasn’t satisfied with this conclusion and sought another import ban on the updated Apple Watch models. Now that the ITC has ruled against that, Masimo is left with the option to appeal the decision with the US Court of Appeals for the Federal Circuit.
While Masimo may currently be on the losing side of this legal battle, it’s confronting Apple on multiple fronts. In November, a federal jury sided with Masimo and ruled that Apple has to pay $634 million in a separate patent infringement case.